Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy.

Wang X, Brea LT, Yu J.

Am J Clin Exp Urol. 2019 Apr 25;7(2):85-91. eCollection 2019. Review.

2.

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.

Emran AA, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR, Hersey P.

Trends Immunol. 2019 Apr;40(4):328-344. doi: 10.1016/j.it.2019.02.004. Epub 2019 Mar 7. Review.

3.

Role of EZH2 in cell lineage determination and relative signaling pathways.

Batool A, Jin C, Liu YX.

Front Biosci (Landmark Ed). 2019 Mar 1;24:947-960. Review.

PMID:
30844722
4.

BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.

Genta S, Pirosa MC, Stathis A.

Curr Oncol Rep. 2019 Feb 4;21(2):13. doi: 10.1007/s11912-019-0762-x. Review.

PMID:
30715616
5.

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies.

Tremblay-LeMay R, Rastgoo N, Pourabdollah M, Chang H.

Biomark Res. 2018 Dec 7;6:34. doi: 10.1186/s40364-018-0148-5. eCollection 2018. Review.

6.

Role of lncRNA and EZH2 Interaction/Regulatory Network in Lung Cancer.

Su M, Xiao Y, Tang J, Wu J, Ma J, Tian B, Zhou Y, Wang H, Yang D, Liao QJ, Wang W.

J Cancer. 2018 Oct 18;9(22):4156-4165. doi: 10.7150/jca.27098. eCollection 2018. Review.

7.

EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers.

Papale M, Ferretti E, Battaglia G, Bellavia D, Mai A, Tafani M.

Front Pediatr. 2018 Nov 19;6:328. doi: 10.3389/fped.2018.00328. eCollection 2018. Review.

8.

Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.

Fioravanti R, Stazi G, Zwergel C, Valente S, Mai A.

Chem Rec. 2018 Dec;18(12):1818-1832. doi: 10.1002/tcr.201800091. Epub 2018 Oct 19. Review.

PMID:
30338896
9.
10.

Emerging EZH2 Inhibitors and Their Application in Lymphoma.

Lue JK, Amengual JE.

Curr Hematol Malig Rep. 2018 Oct;13(5):369-382. doi: 10.1007/s11899-018-0466-6. Review.

PMID:
30112706
11.

EZH2-Related Overgrowth.

Tatton-Brown K, Rahman N.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2013 Jul 18 [updated 2018 Aug 2].

12.

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].

Herviou L, Cavalli G, Moreaux J.

Bull Cancer. 2018 Sep;105(9):804-819. doi: 10.1016/j.bulcan.2018.06.003. Epub 2018 Jul 2. Review. French.

PMID:
30041976
13.

Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Jones BA, Varambally S, Arend RC.

Mol Cancer Ther. 2018 Mar;17(3):591-602. doi: 10.1158/1535-7163.MCT-17-0437. Review.

14.

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.

Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W.

Biomark Res. 2018 Mar 9;6:10. doi: 10.1186/s40364-018-0122-2. eCollection 2018. Review.

15.

Enhancer of zeste homolog 2 (EZH2) inhibitors.

Gulati N, Béguelin W, Giulino-Roth L.

Leuk Lymphoma. 2018 Jul;59(7):1574-1585. doi: 10.1080/10428194.2018.1430795. Epub 2018 Feb 23. Review.

16.

Double sword role of EZH2 in leukemia.

Safaei S, Baradaran B, Hagh MF, Alivand MR, Talebi M, Gharibi T, Solali S.

Biomed Pharmacother. 2018 Feb;98:626-635. doi: 10.1016/j.biopha.2017.12.059. Epub 2017 Dec 29. Review. Erratum in: Biomed Pharmacother. 2018 Mar 8;101:786.

PMID:
29289837
17.

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers.

Alldredge JK, Eskander RN.

Gynecol Oncol Res Pract. 2017 Oct 31;4:17. doi: 10.1186/s40661-017-0052-y. eCollection 2017. Review.

18.

Targeting EZH2 in cancer therapy.

Yamagishi M, Uchimaru K.

Curr Opin Oncol. 2017 Sep;29(5):375-381. doi: 10.1097/CCO.0000000000000390. Review.

PMID:
28665819
19.

[The biological complexity of Polycomb group proteins: the case of EZH2].

Koubi M, Chabannon C, Duprez E.

Med Sci (Paris). 2017 May;33(5):499-505. doi: 10.1051/medsci/20173305013. Epub 2017 Jun 14. Review. French.

20.

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

Yan KS, Lin CY, Liao TW, Peng CM, Lee SC, Liu YJ, Chan WP, Chou RH.

Int J Mol Sci. 2017 May 31;18(6). pii: E1172. doi: 10.3390/ijms18061172. Review.

Supplemental Content

Loading ...
Support Center